Cobra continues to develop robust and scalable process strategies for viral vector manufacturing and production for AAV, lentiviral vectors and adenoviruses, with media development and optimisation (animal component free), for both adherent and suspension modalities.

We have a standardised approach for the production of Ad5 and have experience with different AAV and lenti processes to support our viral vaccine, immuno-oncology and ATMP gene therapy customer requirements.

To improve the quality and productivity of customers’ viral vector products, Cobra has also developed systems to maximise transfection efficiency and harvest parameters and can optimise multiplicity and point of infection (MOI and POI).

Cobra can provide cell banking and viral seed stock production to support customers’ projects from clinical Phase I, II & III to commercial-scale supply. Working within cGMP manufacturing regulations, we can maintain both Master & Working Cell Banks (MCB & WCB) and Viral Seed Stocks (VSS).

Cobra provides analytical support for our customers including analytical method transfer, development, qualification and validation, as well as the development of cell-based potency assays.

Analytical methods for customers’ virus products include reverse phase and ion exchange chromatography, PCR, SDS-PAGE, ELISA, LAL, bioburden, spectrophotometry (UV/visible), fluorimetry, capillary electrophoresis, mass spectrometry, picogreen particle assays, electron microscopy, plaque assays, and TCID assays.